Following an application from Martek Biosciences Corporation submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of docosahexaenoic acid (DHA) and arachidonic acid (ARA) on neural development of the brain and eyes (Question No EFSA-Q-2008-120) [The EFSA Journal (2008) 794, 1-2.]. The claim proposed by the applicant was worded as follows: ‘DHA and ARA support neural development of the brain and eyes’.
Recital 27, Commission Regulation (EC) No 983/2009 of 21 October 2009 on the authorisation and refus…
In forcesince 21 Oct 2009